胃癌前驱病变的全球进展率:系统综述与Meta分析
该系统综述与Meta分析纳入44项研究,按胃癌发病率低(<6/10万)与中/高(≥6/10万)国家分层,采用随机效应模型估算萎缩性胃炎、肠上皮化生和异型增生进展为胃癌的每1000人年进展率。全球合并进展率分别为萎缩性胃炎2.09、肠上皮化生2.89、异型增生10.09;低发病率国家与中/高发病率国家的萎缩性胃炎进展率分别为0.97与2.47(P<.01),肠上皮化生为2.37与3.47(P=.29),异型增生为5.51与14.80(P=.08)。作者认为肠上皮化生和异型增生的进展率在低与中/高发病率国家间相似,需进一步前瞻性研究确认。
要点
- 全球合并每1000人年进展率:萎缩性胃炎2.09、肠上皮化生2.89、异型增生10.09。
- 低与中/高发病率国家萎缩性胃炎进展率0.97 vs 2.47(P<.01)。
- 低与中/高发病率国家肠上皮化生和异型增生进展率无显著差异(P=.29和P=.08)。
核心结论
- 低与中/高胃癌发病率国家的肠上皮化生和异型增生进展率相似,提示低风险地区对这类病变进行监测的潜在获益可能与高风险地区的人群干预相当。
- 需进一步前瞻性研究确认上述发现并为全球筛查与监测指南提供依据。
研究设计与样本
- 系统综述与Meta分析,检索相关数据库纳入报告内镜确诊癌前病变进展为胃癌的研究,共纳入44项研究。
- 研究按胃癌发病率低(<6/10万)与中/高(≥6/10万)国家分层,采用随机效应模型估算每1000人年进展率。
主要发现
- 全球合并每1000人年进展率:萎缩性胃炎2.09(95%CI 1.46-2.99)、肠上皮化生2.89(95%CI 2.03-4.11)、异型增生10.09(95%CI 5.23-19.49)。
- 低与中/高发病率国家萎缩性胃炎进展率分别为0.97(95%CI 0.86-1.10)与2.47(95%CI 1.70-2.99),P<.01。
- 低与中/高发病率国家肠上皮化生进展率分别为2.37(95%CI 1.43-3.92)与3.47(95%CI 2.13-5.65),P=.29。
- 低与中/高发病率国家异型增生进展率分别为5.51(95%CI 2.92-10.39)与14.80(95%CI 5.87-37.28),P=.08。
- 比较高质量研究时,两组间萎缩性胃炎进展无差异。
关键数值与推荐
- 胃癌发病率分层阈值:低发病率国家<6/10万,中/高发病率国家≥6/10万。
- 进展率单位为每1000人年,采用随机效应模型合并。
临床怎么用
- 作者认为低风险地区对肠上皮化生和异型增生进行监测的潜在获益可能与高风险地区的人群干预相当。
- 作者指出需进一步前瞻性研究确认上述发现并为全球筛查与监测指南提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Whether gastric cancer (GC) precursor lesions progress to invasive cancer at similar rates globally remains unknown. We conducted a systematic review and meta-analysis to determine the progression of precursor lesions to GC in countries with low versus medium/high incidence. METHODS: We searched relevant databases for studies reporting the progression of endoscopically confirmed precursor lesions to GC. Studies were stratified by low (<6 per 100,000) or medium/high (≥6 per 100,000) GC incidence countries. Random-effects models were used to estimate the progression rates of atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia to GC per 1000 person-years. RESULTS: Among the 5829 studies identified, 44 met our inclusion criteria. The global pooled estimates of the progression rate per 1000 person-years were 2.09 (95% confidence interval, 1.46-2.99), 2.89 (2.03-4.11), and 10.09 (5.23-19.49) for AG, IM, and dysplasia, respectively. The estimated progression rates per 1000 person-years for low versus medium/high GC incidence countries, respectively, were 0.97 (0.86-1.10) versus 2.47 (1.70-2.99) for AG (P < .01), 2.37 (1.43-3.92) versus 3.47 (2.13-5.65) for IM (P = .29), and 5.51 (2.92-10.39) versus 14.80 (5.87-37.28) for dysplasia (P = .08). There were no differences for progression of AG between groups when high-quality studies were compared. CONCLUSIONS: Similar progression rates of IM and dysplasia were observed among low and medium/high GC incidence countries. This suggests that the potential benefits of surveillance for these lesions in low-risk regions may be comparable with those of population-wide interventions in high-risk regions. Further prospective studies are needed to confirm these findings and inform global screening and surveillance guidelines.
引用
- Hahn AI, Mülder DT, Huang RJ, et al. Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39362617. doi:10.1016/j.cgh.2024.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。